Patent 9663480 was granted and assigned to Ratiopharm on May, 2017 by the United States Patent and Trademark Office.
The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel medicaments, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, or inflammatory diseases, for example multiple sclerosis and psoriasis.